Laddar...
The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
BACKGROUND/AIM: Ruxolitinib, a JAK/STAT signaling pathway inhibitor targeted drug, has been approved for the controlling of disease symptoms and splenomegaly in patients with myeloproliferative neoplastic diseases. Recently, it has been proposed that ruxolitinib-induced JAK/STAT pathway inhibition i...
Sparad:
| I publikationen: | Turk J Med Sci |
|---|---|
| Huvudupphovsmän: | , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
The Scientific and Technological Research Council of Turkey
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7018380/ https://ncbi.nlm.nih.gov/pubmed/30997981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3906/sag-1807-152 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|